Skip to main content

Valsartan Blamed For Lung And Pancreatic Cancer

Valsartan Blamed For Lung And Pancreatic Cancer

Valsartan Blamed For Lung And Pancreatic Cancer

Introduction

In the latest complaint filed by a couple in the U.S. District Court for the Eastern District of Kentucky on May 29, Camber Pharmaceuticals, Hetero USA, Inc., and The Kroger Company have been alleged for selling defective and dangerous generic versions of the blood pressure drug valsartan.

The husband started using generic valsartan pills for treatment of his high blood pressure and heart failure conditions since 2013. He complained that he was diagnosed with lung and pancreatic cancer in September 2017 following the exposure to the pills that were recalled in recent months due to the presence of cancer-causing chemicals N-nitrosodimethylamine (NDMA) or N-Nitrosodiethylamine (NDEA). The defendants further face allegations of manufacturing and design defects, failure to warn,  negligence, gross negligence, breach of warranty, fraud, negligent misrepresentation, violation of the Kentucky Consumer Protection Act, and loss of consortium. The plaintiffs have claimed compensatory and punitive damages.

There are currently 10 class action lawsuits and one individual action pending in District Courts across the U.S. against Valsartan. Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!